Regenxbio files second patent infringement suit against Sarepta

Regenxbio (RGNX) announced that it has filed a second complaint for patent infringement against Sarepta Therapeutics (SRPT) arising from Sarepta’s manufacture, use and imminent commercial launch of SRP-9001 for the treatment of Duchenne muscular dystrophy. The complaint asserted U.S. Patent No. 11,680,274, which covers Sarepta’s AAVrh74-based gene therapy vector products, including SRP-9001. Regenxbio exclusively licensed the newly issued patent from the University of Pennsylvania, which is a joint plaintiff in the lawsuit. The term of the patent-in-suit extends to October 2027 and damages are being sought to compensate Regenxbio and its licensor, Penn, which originated the adeno-associated virus gene therapy technology.